BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock: Price, Forecast & Analyst Target
BridgeBio Oncology Therapeutics, Inc. (BBOT) — MoonshotScore 27/100 (Weak band), calculated Nov 18, 2026. Price $1.81 (-2.69%), as of the Nov 20, 2026 trading session; market cap $145M.
Educational signal · not a buy or sell recommendation · How to read this
BridgeBio Oncology Therapeutics, Inc. · BBOT · NASDAQ
BridgeBio Oncology Therapeutics Inc.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · BridgeBio Oncology Therapeutics (BBOT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.
Free cash flow yield is the main valuation drag relative to sector peers.
- EPS beat 2 of the last 5 reports
- Altman Z -1.35 · Piotroski F 1
- ROE -46.4% · ROA -28.2% · current ratio 4.08
Holding back: a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.81 | |
| Change on the day | -2.69% | |
| Market capitalisation | $145M | — |
| Shares traded on the day | 451.0K |
Price & events
Other perspectives
Council score for BridgeBio Oncology Therapeutics (BBOT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is BridgeBio Oncology Therapeutics (BBOT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BridgeBio Oncology Therapeutics, Inc. (BBOT) is listed on NASDAQ. It employs 84 people. The market values it at $145M.
What do the latest results show for BridgeBio Oncology Therapeutics (BBOT)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 5 reports.
What are the financial strengths and risks for BridgeBio Oncology Therapeutics (BBOT)?
Short answer
What is holding it back is a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -1.35 · Piotroski F 1. Trailing ratios: ROE -46.4% · ROA -28.2% · current ratio 4.08.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.35 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-46.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at BridgeBio Oncology Therapeutics (BBOT)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -2.32 · 0 analysts. Current published price targets run low $15.00 · high $22.00 · consensus $19.00 · median $20.00 against a quoted price of $1.81 (as of Nov 20, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for BBOT.
Checked against the records this page reads, on the dates shown above.
How does BridgeBio Oncology Therapeutics compare with its peers?
Short answer
BridgeBio Oncology Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $41.19 Nov 19, 2026 | $776M | 88 5-pillar Nov 18, 2026 | |
| $11.17 Nov 19, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $15.52 Nov 19, 2026 | $86.9M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| BridgeBio Oncology Therapeutics (BBOT) — this page | $1.81 | $145M | 27 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $15.00 – $22.00
- Consensus target
- $19.00
- Median target
- $20.00
- Revenue estimate
- $0.00
- EPS estimate
- $-2.32
Consensus record · Captured .
Measured against a quoted price of $1.81 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BBOT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BBOT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BridgeBio Oncology Therapeutics (BBOT)?
- JPMorgan Adjusts Price Target for BridgeBio Oncology Therapeutics
- BridgeBio Oncology Therapeutics Reports Third Quarter 2026 Financial Results
- Wedbush Adjusts Price Target on BridgeBio Oncology Therapeutics
- Wedbush Cuts Price Target on BridgeBio Oncology Therapeutics to $9 From $25, Maintains Outperform Rating
What Investors Ask About BridgeBio Oncology Therapeutics (BBOT)
These answers are editorial: 1 of these 9 answers is drawn from the BBOT research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BBOT?
BBOT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is BBOT a good stock to buy?
Stock Expert AI does not rate BBOT buy, sell or hold. BridgeBio Oncology Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BBOT stock price today?
The last price recorded for BridgeBio Oncology Therapeutics, Inc. (BBOT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BBOT price target?
The analyst consensus price target for BridgeBio Oncology Therapeutics, Inc. (BBOT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
How does BridgeBio Oncology Therapeutics Inc. manage patent expiration risks?
As a clinical-stage company, BridgeBio Oncology Therapeutics Inc. is focused on securing and maintaining strong patent protection for its pipeline programs.
What are the key factors to evaluate for BBOT?
BridgeBio Oncology Therapeutics, Inc. (BBOT) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does BBOT data refresh on this page?
BBOT's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BBOT's recent stock price performance?
BridgeBio Oncology Therapeutics, Inc. (BBOT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BBOT overvalued or undervalued right now?
BridgeBio Oncology Therapeutics, Inc. (BBOT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com